Information de reference pour ce titreAccession Number: | 00000429-201804010-00016.
|
Author: | Wu, Pingsheng; Escobar, Gabriel J; Gebretsadik, Tebeb; Carroll, Kecia N; Li, Sherian X; Walsh, Eileen M; Mitchel, Edward F; Sloan, Chantel; Dupont, William D; Yu, Chang; Horner, Jeffrey R; Hartert, Tina V
|
Institution: | Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee Department of Inpatient Pediatrics, Kaiser Permanente Medical Center, Walnut Creek, California Perinatal Research Unit, Division of Research, Kaiser Permanente Northern California, Oakland, California Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee Department of Health Science, College of Life Sciences, Brigham Young University, Provo, Utah
|
Title: | |
Source: | American Journal of Epidemiology. 187(7):1490-1500, July 2018.
|
Author Keywords: | bronchiolitis; bronchiolitis hospitalization; high-risk infants; immunoprophylaxis; infancy; lower respiratory tract infection; respiratory syncytial virus.
|
References: | 1. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543-546.
2. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917-1928.
3. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440-1446.
4. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics. 1997;99(4):645-650.
5. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415-420.
6. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791-1799.
7. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 1993;329(21):1524-1530.
8. O'Brien KL, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis. 2015;15(12):1398-1408.
9. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531-537.
10. Nightingale SL. First product available for preventing serious RSV disease. JAMA. 1996;275(12):902.
11. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102(5):1211-1216.
12. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-1701.
13. Pickering LK, Baker CJ, Long SS, et al., eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.
14. Canfield SD, Simoes EA. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics). Pediatr Ann. 1999;28(8):507-514.
15. Escobar GJ, Gebretsadik T, Carroll K, et al. Adherence to immunoprophylaxis regimens for respiratory syncytial virus infection in insured and Medicaid populations. J Pediatric Infect Dis Soc. 2013;2(3):205-214.
16. Islam JY, Keller RL, Aschner JL, et al. Understanding the short- and long-term respiratory outcomes of prematurity and bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2015;192(2):134-156.
17. Poindexter BB, Feng R, Schmidt B, et al. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program. Ann Am Thorac Soc. 2015;12(12):1822-1830.
18. Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17(2):110-115.
19. Carroll KN, Wu P, Gebretsadik T, et al. Season of infant bronchiolitis and estimates of subsequent risk and burden of early childhood asthma. J Allergy Clin Immunol. 2009;123(4):964-966.
20. Wu P, Dupont WD, Griffin MR, et al. Evidence of a causal role of winter virus infection during infancy in early childhood asthma. Am J Respir Crit Care Med. 2008;178(11):1123-1129.
21. Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J. 2006;25(9):795-800.
22. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer Science & Business Media; 2000.
23. Carroll KN, Gebretsadik T, Escobar GJ, et al. Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma. J Allergy Clin Immunol. 2017;139(1):66.e3-71.e3.
24. Eaglstein WH, Kirsner RS. Expectations for comparative effectiveness and efficacy research: with welcomed questions may come unwelcome answers. JAMA Dermatol. 2013;149(1):18-19.
25. Winterstein AG, Hampp C, Saidi A. Effectiveness of palivizumab prophylaxis in infants and children in Florida. Pharmacoepidemiol Drug Saf. 2012;21(1):53-60.
26. MedImmune LLC. Synagis. Palivizumab. (Package insert). Gaithersburg, MD: MedImmune LLC; 2014.
27. Sahni R, Ammari A, Suri MS, et al. Is the new definition of bronchopulmonary dysplasia more useful?J Perinatol. 2005;25(1):41-46.
28. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116(6):1353-1360.
29. Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 2007;196(2):147.e1-147e8.
30. Atkins JT, Karimi P, Morris BH, et al. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost. Pediatr Infect Dis J. 2000;19(2):138-143.
31. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, et al. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22(9):823-827.
32. Boyce TG, Yogev R, DeVincenzo JP, et al. Confounding by indication limits conclusions of study of palivizumab effectiveness. Pediatrics. 2017;139(3):e20164247A.
33. Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341-e348.
34. Makari D, Staat MA, Henrickson KJ, et al. The underrecognized burden of respiratory syncytial virus among infants presenting to US emergency departments. Clin Pediatr (Phila). 2015;54(6):594-597.
35. Henrickson KJ, Hoover S, Kehl KS, et al. National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr Infect Dis J. 2004;23(1 suppl):S11-S18.
36. Meissner HC. Viral bronchiolitis in children. N Engl J Med. 2016;374(1):62-72.
37. Smyth RL, Openshaw PJ. Bronchiolitis. Lancet. 2006;368(9532):312-322.
38. Krilov LR, Masaquel AS, Weiner LB, et al. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis. BMC Pediatr. 2014;14:261.
39. La Via WV, Notario GF, Yu XQ, et al. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther. 2013;26(6):666-671.
40. Robbie GJ, Zhao L, Mondick J, et al. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56(9):4927-4936.
41. Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;(4):CD006602.
|
Language: | English.
|
Document Type: | Original contributions.
|
Journal Subset: | Public Health.
|
ISSN: | 0002-9262
|
NLM Journal Code: | 3h3, 7910653
|
DOI Number: | https://dx.doi.org/10.1093/aje/k...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|